Doppler Image

Marketplace Links

Social Links

Main Menu

WRALTechWire 30
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
OncoGenex Pharmaceuticals, Inc. (NQ: OGXI)
10.73 USD  +0.09 (+0.85%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 10.62
Bid (Size) 10.73 (300)
Ask (Size) 10.74 (4700)
Prev. Close 10.64
Today's Range 10.51 - 10.74
52wk Range 9.160 - 14.99
Shares Outstanding 14,670,395
Dividend Yield N/A
Top News
More News
OncoGenex Plans Cedar Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer
May 23, 2013
OncoGenex Pharmaceuticals (NASDAQ: OGXI ) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in... Read More
category Benzinga , Global , Guidance , and 2 more.
from Latest Articles from Benzinga.com
OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer
May 23, 2013
OGX-427 ORCA™ Program Expands to Include Second Phase 2 Trial in Patients with Advanced Lung Cancer Read More
from PR Newswire

More News
Read More
OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting
May 22, 2013
from PR Newswire
OncoGenex Pharmaceuticals Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
May 02, 2013
category Benzinga , TEVA , OGXI , and 2 more.
from Latest Articles from Benzinga.com
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
May 02, 2013
from PR Newswire
OncoGenex Pharmaceuticals, Inc. Becomes Oversold (OGXI)
May 01, 2013
category Stocks
from Market News Video
OncoGenex to Initiate Rainier Clinical Trial Evaluating OGX-427 with ABRAXANE plus Gemcitabine
May 01, 2013
category Contracts , Management , Benzinga , and 4 more.
from Latest Articles from Benzinga.com
OncoGenex (OGXI) to Initiate OGX-427 Phase 2 in Combo with ABRAXANE
May 01, 2013
from StreetInsider.com News Articles
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
May 01, 2013
from PR Newswire
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment
April 30, 2013
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
advertisement